Global patent index - EP 1001972 A1

EP 1001972 A1 2000-05-24 - SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4

Title (en)

SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4

Title (de)

SUBSTITUIERTE PHENYLALANIN-DERIVATE, DIE DIE VLA-4 VERMITTELTE ADHÄSION VON LEUKOZYTEN INHIBIEREN

Title (fr)

COMPOSES DE TYPE PHENYLALANINE SUBSTITUEE INHIBANT UNE ADHESION DE LEUCOCYTES REGULEE PAR VLA-4

Publication

EP 1001972 A1 (EN)

Application

EP 98937990 A

Priority

  • US 9815313 W
  • US 92039497 A

Abstract (en)

[origin: WO9906431A1] Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds are also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

IPC 1-7 (main, further and additional classification)

C07K 5/062; A61K 38/05; C07K 5/065; C07K 5/078

IPC 8 full level (invention and additional information)

A61K 38/00 (2006.01); A61P 9/10 (2006.01); A61P 11/06 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 5/06 (2006.01); C07K 5/062 (2006.01); C07K 5/065 (2006.01); C07K 5/078 (2006.01)

CPC (invention and additional information)

C07K 5/06139 (2013.01); C07K 5/06026 (2013.01); C07K 5/0606 (2013.01); C07K 5/06078 (2013.01); C07K 5/06165 (2013.01); A61K 38/00 (2013.01)

Citation (search report)

See references of WO 9906431A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9906431 A1 19990211; AR 013384 A1 20001227; AU 756696 B2 20030123; AU 8661198 A 19990222; BR 9812114 A 20000718; CA 2290747 A1 19990211; CN 1133648 C 20040107; CN 1265668 A 20000906; EP 1001972 A1 20000524; HU 0004259 A2 20010428; HU 0004259 A3 20010528; IL 133640 D0 20010430; JP 2001512134 A 20010821; NO 20000450 A 20000328; NO 20000450 D0 20000128; NZ 502582 A 20020726; PL 338423 A1 20001106; TW 534910 B 20030601; ZA 9806827 B 20000502

INPADOC legal status

2007-03-09 [REG HK WD] APPLICATIONS WITHDRAWN, DEEMED TO BE WITHDRAWN, OR REFUSED AFTER PUBLICATION IN HONG KONG

- Ref Legal Event Code: WD

- Ref Document Number: 1026435

- Country of Ref Document: HK

2006-08-23 [18D] DEEMED TO BE WITHDRAWN

- Ref Legal Event Code: 18D

- Effective date: 20060201

2002-12-04 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: ELAN PHARMACEUTICALS, INC.

- Ref Legal Event Code: RAP1

2002-12-04 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: WYETH

- Ref Legal Event Code: RAP1

2000-05-24 [17P] REQUEST FOR EXAMINATION FILED

- Ref Legal Event Code: 17P

- Effective date: 20000225

2000-05-24 [AK] DESIGNATED CONTRACTING STATES:

- Ref Legal Event Code: AK

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2000-05-24 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO

- Ref Legal Event Code: AX

- Free Format Text: AL PAYMENT 20000225;LT PAYMENT 20000225;LV PAYMENT 20000225;MK PAYMENT 20000225;RO PAYMENT 20000225;SI PAYMENT 20000225